Advancing Curative Therapies for Autoimmune Diseases  Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. Agenda highlights include: Standardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy […]

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum. It’s not just investments that are gaining traction. Recent approvals are changing […]

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With […]

4th mRNA Analytical Development & Quality Control Summit | February 25-27, 2025 Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running. Yet, despite optimized analytics, critical quality control methodology and robust assay development leading to efficient approvals and commercialization, knowledge gaps persist in phase-appropriate assays, analyzing […]

2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination approaches all take off! So, we are proud to announce the 10th Anniversary Innate Killer Summit returning to San Diego this March, to showcase all […]

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge in multi-billion-dollar acquisitions, commercialisation deals, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments […]

In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit, uniting AD, QC and regulatory experts, this summit works to design potency assays that not only conform to changing guidelines but also streamline […]

Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However, challenges persist, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access, managing global supply chains, importation, licensing, […]

With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. Returning to Boston in March, the 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare […]

In today’s complex drug development landscape, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery […]

The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals, which paves the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs. The 4th Novel Conjugates Summit is the only event offering comprehensive […]

With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However, challenges in biologics formulation, along with renewed interest from major pharmaceutical companies […]

The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025, bringing together over 80 experts in peptide computational science, medicinal chemistry, and formulation to discuss the latest advancements shaping the next generation of peptide-based therapies—from early-stage discovery to clinical application. Download the three-day program here: https://ter.li/rrvg1v This year’s summit will highlight groundbreaking innovations […]